Life Sciences

Multiple Myeloma Drug Market in China 2021

The multiple myeloma drug market in China in terms of revenue is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 18.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the multiple myeloma drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

Oncology Drug Market in China 2021

The oncology drug market in China in terms of revenue is set to grow by US$ 42 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 13.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the oncology drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

Moderate and Severe Dry Eye Disease Market in China 2021

The moderate and severe dry eye disease market in China in terms of revenue is set to grow by US$ 570 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 30.4% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the moderate and severe dry eye disease market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

NMOSD (Neuromyelitis Optica Spectrum Disorder) Drug Market in China 2021

In terms of revenue, the NMOSD (neuromyelitis optica spectrum disorder) drug market in China is projected to grow at a compound annual growth rate (CAGR) of 26.8% over the analysis period of 2021 to 2027, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the NMOSD (neuromyelitis optica spectrum disorder) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

MG (Myasthenia Gravis) Drug Market in China 2021

The MG (myasthenia gravis) drug market in China in terms of revenue is set to grow by US$ 565 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 51% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the MG (myasthenia gravis) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

ITP (Immune Thrombocytopenia) Drug Market in China 2021

The ITP (immune thrombocytopenia) drug market in China in terms of revenue is set to grow by US$ 714 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 25.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the ITP (immune thrombocytopenia) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

Therapeutic Antibody Market in China 2021

The therapeutic antibody market in China in terms of revenue is set to grow by US$ 41 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 30.4% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the therapeutic antibody market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

Online Retail Pharmacy Market in China 2021

The online retail pharmacy market in China in terms of revenue is set to grow by US$ 146 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 33.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the online retail pharmacy market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

Digital Health and Wellness Market in China 2021

The digital health and wellness market in China in terms of revenue is set to grow by US$ 199 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 30.7% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the digital health and wellness market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

Health and Wellness Market in China 2021

The health and wellness market in China in terms of revenue is set to grow by US$ 1,044 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 9.4% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the health and wellness market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Read More →

Let us know what you are looking for and we will get back to you

Our clients

Driving key projects for leading brands

login